NeoGenomics, Inc., together with its subsidiaries, operates a network of cancer-focused genetic testing laboratories in the United States. It operates through Clinical Services and Pharma Services segments. The company laboratories provide genetic and molecular testing services to hospitals, pathologists, oncologists, urologists, other clinicians and researchers, pharmaceutical firms, and other clinical laboratories. It offers cytogenetics testing services to study normal and abnormal chromosomes and their relationship to diseases; fluorescence in-situ hybridization testing services that focus on detecting and locating the presence or absence of specific DNA sequences and genes on chromosomes; flow cytometry testing services to measure the characteristics of cell populations; immunohistochemistry and digital imaging testing services to localize proteins in cells of a tissue section, as well as to allow clients to see and utilize scanned slides, and perform quantitative analysis for various stains; and molecular testing services that focus on the analysis of DNA and RNA, and the structure and function of genes at the molecular level. The company also provides pathology consultation services for clients in which its pathologists review surgical samples on a consultative basis; and testing services in support of its pharmaceutical clients' oncology programs, as well as acts as a reference laboratory supplying anatomic pathology testing services. The company has a strategic alliance with Pharmaceutical Product Development Inc. NeoGenomics, Inc. was founded in 2001 and is headquartered in Fort Myers, Florida.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry Testing laboratories
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:NEO
Previous Symbol
CUSIPN/A
Phone239-768-0600
Debt
Debt-to-Equity Ratio0.32
Current Ratio4.13
Quick Ratio3.98
Price-To-Earnings
Trailing P/E Ratio236.50
Forward P/E Ratio129.00
P/E GrowthN/A
Sales & Book Value
Annual Sales$258.61 million
Price / Sales5.10
Cash Flow$0.4775 per share
Price / Cash Flow29.72
Book Value$2.15 per share
Price / Book6.60
Profitability
EPS (Most Recent Fiscal Year)$0.06
Net Income$-840,000.00
Net Margins1.70%
Return on Equity2.63%
Return on Assets1.43%
Miscellaneous
Employees1,030
Outstanding Shares93,020,000
Market Cap$1.32 billion
OptionableOptionable
NeoGenomics (NASDAQ:NEO) Frequently Asked Questions
What is NeoGenomics' stock symbol?
NeoGenomics trades on the NASDAQ under the ticker symbol "NEO."
How were NeoGenomics' earnings last quarter?
NeoGenomics, Inc. (NASDAQ:NEO) posted its earnings results on Tuesday, October, 30th. The medical research company reported $0.05 EPS for the quarter, topping the Thomson Reuters' consensus estimate of $0.02 by $0.03. The medical research company had revenue of $69.10 million for the quarter, compared to the consensus estimate of $66.13 million. NeoGenomics had a net margin of 1.70% and a return on equity of 2.63%. The business's quarterly revenue was up 16.8% on a year-over-year basis. During the same period in the prior year, the business posted $0.01 earnings per share. View NeoGenomics' Earnings History.
When is NeoGenomics' next earnings date?
What guidance has NeoGenomics issued on next quarter's earnings?
NeoGenomics issued an update on its FY18 earnings guidance on Tuesday, October, 30th. The company provided earnings per share guidance of $0.17-0.19 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $0.16. The company issued revenue guidance of $266.88 million, compared to the consensus revenue estimate of prior $0.12-0.17.
What price target have analysts set for NEO?
10 analysts have issued 1-year price targets for NeoGenomics' stock. Their forecasts range from $15.00 to $24.00. On average, they anticipate NeoGenomics' share price to reach $20.2727 in the next year. This suggests a possible upside of 42.9% from the stock's current price. View Analyst Price Targets for NeoGenomics.
What is the consensus analysts' recommendation for NeoGenomics?
10 Wall Street analysts have issued "buy," "hold," and "sell" ratings for NeoGenomics in the last year. There are currently 2 hold ratings and 8 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for NeoGenomics.
What are Wall Street analysts saying about NeoGenomics stock?
Here are some recent quotes from research analysts about NeoGenomics stock:
- 1. According to Zacks Investment Research, "NeoGenomics, Inc. is a high-complexity CLIA-certified clinical laboratory that specializes in cancer genetics diagnostic testing, the fastest growing segment of the laboratory industry. The company's testing services include cytogenetics, fluorescence in-situ hybridization, flow cytometry, morphology studies, anatomic pathology and molecular genetic testing. Headquartered in Fort Myers, FL, NeoGenomics has labs in Nashville, TN, Irvine, CA and Fort Myers and services the needs of pathologists, oncologists, urologists, hospitals and other reference laboratories throughout the United States. " (11/3/2018)
- 2. BTIG Research analysts commented, "Raising Our PT Earlier this week, we hosted investor meetings with Chairman and CEO Bill Bonello. The general tone was upbeat with majority of the discussions focused on the oncology market opportunity, competitive landscape given recent M&A and use of cash. We felt the overarching theme was the breadth of NEO’s testing capabilities being a competitive differentiator particularly on the clinical trial side. The recently announced agreement with PPD (Private) to be the chief oncology provider would be upside to our current estimates. We are increasing our target EV/sales multiple and PT to $15 (from $11) on increased confidence in Pharma Services, and continued market share capture of clinical testing. Additionally, as NEO moves upstream into higher-end testing, we feel its multiple should more closely match those of specialty cancer testing peers." (6/21/2018)
Has NeoGenomics been receiving favorable news coverage?
News coverage about NEO stock has been trending somewhat positive recently, InfoTrie reports. The research group identifies negative and positive media coverage by analyzing more than six thousand news and blog sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores closest to five being the most favorable. NeoGenomics earned a daily sentiment score of 0.8 on InfoTrie's scale. They also gave news coverage about the medical research company a news buzz of 1.0 out of 10, indicating that recent media coverage is extremely unlikely to have an impact on the stock's share price in the immediate future.
Who are some of NeoGenomics' key competitors?
Some companies that are related to NeoGenomics include HYPERA S A/S (HYPMY), Amneal Pharmaceuticals (AMRX), GALAPAGOS NV/S (GLPG), Premier (PINC), GN STORE NORD A/ADR (GNNDY), Sartorius (SARTF), Syneos Health (SYNH), Amarin (AMRN), ORION OYJ/ADR (ORINY), Chemed (CHE), SAGE Therapeutics (SAGE), Insulet (PODD), United Therapeutics (UTHR), DiaSorin (DSRLF) and ICU Medical (ICUI).
Who are NeoGenomics' key executives?
NeoGenomics' management team includes the folowing people:
- Mr. Douglas M. VanOort, Chairman & CEO (Age 63)
- Mr. George A. Cardoza, Pres of Pharma Services Division (Age 56)
- Mr. Robert J. Shovlin, Pres of Clinical Services Division (Age 47)
- Dr. Steven G. Brodie, VP of Worldwide Pharma Services Operations (Age 57)
- Ms. Sharon A. Virag, Chief Financial Officer (Age 51)
Who are NeoGenomics' major shareholders?
NeoGenomics' stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include Janus Henderson Group PLC (7.48%), BlackRock Inc. (6.22%), Vanguard Group Inc. (4.13%), First Light Asset Management LLC (3.98%), Eagle Asset Management Inc. (2.64%) and Carillon Tower Advisers Inc. (2.15%). Company insiders that own NeoGenomics stock include Alison L Hannah, Electric Co General, Jennifer Balliet, Kevin C Johnson, Lynn A Tetrault, Robert J Shovlin, Steven A Ross, Steven C Jones and Steven G Brodie. View Institutional Ownership Trends for NeoGenomics.
Which institutional investors are selling NeoGenomics stock?
NEO stock was sold by a variety of institutional investors in the last quarter, including First Light Asset Management LLC, Russell Investments Group Ltd., Falcon Point Capital LLC, FineMark National Bank & Trust, Uniplan Investment Counsel Inc., Cowen Prime Services LLC, Penn Capital Management Co. Inc. and Janus Henderson Group PLC. Company insiders that have sold NeoGenomics company stock in the last year include Electric Co General, Jennifer Balliet, Kevin C Johnson, Lynn A Tetrault, Robert J Shovlin, Steven A Ross and Steven C Jones. View Insider Buying and Selling for NeoGenomics.
Which institutional investors are buying NeoGenomics stock?
NEO stock was bought by a variety of institutional investors in the last quarter, including Eagle Asset Management Inc., Carillon Tower Advisers Inc., Brown Advisory Inc., Emerald Mutual Fund Advisers Trust, BlackRock Inc., Morgan Stanley, Vanguard Group Inc. and Franklin Resources Inc.. View Insider Buying and Selling for NeoGenomics.
How do I buy shares of NeoGenomics?
Shares of NEO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is NeoGenomics' stock price today?
One share of NEO stock can currently be purchased for approximately $14.19.
How big of a company is NeoGenomics?
NeoGenomics has a market capitalization of $1.32 billion and generates $258.61 million in revenue each year. The medical research company earns $-840,000.00 in net income (profit) each year or $0.06 on an earnings per share basis. NeoGenomics employs 1,030 workers across the globe.
What is NeoGenomics' official website?
How can I contact NeoGenomics?
NeoGenomics' mailing address is 12701 COMMONWEALTH DRIVE SUITE 9, FORT MYERS FL, 33913. The medical research company can be reached via phone at 239-768-0600 or via email at [email protected]
MarketBeat Community Rating for NeoGenomics (NASDAQ NEO)
MarketBeat's community ratings are surveys of what our community members think about NeoGenomics and other stocks. Vote "Outperform" if you believe NEO will outperform the S&P 500 over the long term. Vote "Underperform" if you believe NEO will underperform the S&P 500 over the long term. You may vote once every thirty days.
